Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Overall Survival in 7/8 HLA-Matched Hematopoietic Stem Cell Transplantation Patients Treated With Abatacept Combined With a Calcineurin Inhibitor and Methotrexate- An Analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) Database

NCT05421299 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05421299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05421299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Overall Survival in 7/8 HLA-Matched Hematopoietic Stem Cell Transplantation Patients Treated With Abatacept Combined With a Calcineurin Inhibitor and Methotrexate- An Analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) Database
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
September 16, 2019
Completion date
February 15, 2021
Enrollment
378 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stem cell transplantation